The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Open accessAbstract
Although the Th17 subset and its signature cytokine, interleukin (IL)-17A (IL-17), are implicated in certain autoimmune diseases, their role in cancer remains to be further explored. IL-17 has been shown to be elevated in several types of cancer, but how it might contribute to tumor growth is still unclear. We show that growth of B16 melanoma and MB49 bladder carcinoma is reduced in IL-17−/− mice but drastically accelerated in IFN-γ−/− mice, contributed to by elevated intratumoral IL-17, indicating a role of IL-17 in promoting tumor growth. Adoptive transfer studies and analysis of the tumor microenvironment suggest that CD4+ T cells are the predominant source of IL-17. Enhancement of tumor growth by IL-17 involves direct effects on tumor cells and tumor-associated stromal cells, which bear IL-17 receptors. IL-17 induces IL-6 production, which in turn activates oncogenic signal transducer and activator of transcription (Stat) 3, up-regulating prosurvival and proangiogenic genes. The Th17 response can thus promote tumor growth, in part via an IL-6–Stat3 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Self-citationInterferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
TH-17 cells in the circle of immunity and autoimmunity
Bettelli, E., Oukka, M., & Kuchroo, V. K. (2007) · Nature Immunology · doi:10.1038/ni0407-345 · Cited by 1,517
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 6×
“The immune system can act as an extrinsic suppressor of tumors, and the importance of Th1, characterized by IFN- and type 1 IFNs, in inhibiting tumor incidence and growth has been established (Kaplan et al., 1998; Dunn et al., 2006).”
BackgroundResultInfluentialKhader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel-Moreno, J., Cilley, G. E., Shen, F., Eaton, S. M., Gaffen, S. L., Swain, S. L., et al. (2007) · Nature Immunology · doi:10.1038/ni1449 · Cited by 1,439
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422 · cited 2×
“A major advance in understanding the role of various T cell subsets in disease has been the recent identification of the Th17 subset, characterized by the production of IL-17A (IL-17), as well as the related IL-17F cytokine (Weaver et al., 2006).”
BackgroundHirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,190
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Self-citationInflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Self-citationMacrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
The impact of the endoplasmic reticulum protein-folding environment on cancer development
Wang, M., & Kaufman, R. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3800 · Cited by 1,112
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Microbiota organization is a distinct feature of proximal colorectal cancers
Dejea, C. M., Wick, E. C., Hechenbleikner, E. M., White, J. R., Mark Welch, J. L., Rossetti, B. J., Peterson, S. N., Snesrud, E. C., Borisy, G. G., Lazarev, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406199111 · Cited by 700
Self-citationIL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Zamarron, B. F., & Chen, W. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.651 · Cited by 681
Candido, J., & Hagemann, T. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9847-0 · Cited by 653
Chung, L., Thiele Orberg, E., Geis, A. L., Chan, J. L., Fu, K., DeStefano Shields, C. E., Dejea, C. M., Fathi, P., Chen, J., Finard, B. B., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.007 · Cited by 644
Self-citationTH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Chronic Inflammation in Cancer Development
Multhoff, G., Molls, M., & Radons, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00098 · Cited by 576
Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Sole, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 575
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
Self-citationThe parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
Interleukin 17 is a chief orchestrator of immunity
Veldhoen, M. (2017) · Nature Immunology · doi:10.1038/ni.3742 · Cited by 475
Inflammation and oncogenesis: a vicious connection
Grivennikov, S. I., & Karin, M. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.004 · Cited by 456
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
Gut microbiota promotes tumor growth in mice by modulating immune response
Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., Zhang, L., Sharma, U., Giri, B., Garg, B., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.001 · Cited by 403
Mechanistic links between COPD and lung cancer
Houghton, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3477 · Cited by 414
McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405
Self-citationSTAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395
“In addition to mediating tumor cell proliferation and survival in a tumor cell–autonomous manner, IL-6–STAT3 signaling is crucial for inflammatory cell-mediated transformation and tumor progressio”
BackgroundSelf-citationEssentials of Th17 cell commitment and plasticity
Muranski, P., & Restifo, N. P. (2013) · Blood · doi:10.1182/blood-2012-09-378653 · Cited by 383
Bollrath, J., & Greten, F. R. (2009) · EMBO reports · doi:10.1038/embor.2009.243 · Cited by 383
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Self-citation“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Bousoik, E., & Montazeri Aliabadi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 376
The metastasis-promoting roles of tumor-associated immune cells
Smith, H. A., & Kang, Y. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1021-5 · Cited by 367
Zhang, C., Yue, C., Herrmann, A., Song, J., Egelston, C., Wang, T., Zhang, Z., Li, W., Lee, H., Aftabizadeh, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.013 · Cited by 366
Self-citationTh9 cells promote antitumor immune responses in vivo
Lu, Y., Hong, S., Li, H., Park, J., Hong, B., Wang, L., Zheng, Y., Liu, Z., Xu, J., He, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65459 · Cited by 361
Self-citationInterleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 359
Interleukin-17 and its expanding biological functions
Xu, S., & Cao, X. (2010) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.21 · Cited by 357
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 340
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P.-Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1110765 · Cited by 339
Self-citationChalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
He, D., Li, H., Yusuf, N., Elmets, C. A., Li, J., Mountz, J. D., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902574 · Cited by 334
T helper 17 cells play a critical pathogenic role in lung cancer
Chang, S. H., Mirabolfathinejad, S. G., Katta, H., Cumpian, A. M., Gong, L., Caetano, M. S., Moghaddam, S. J., & Dong, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319051111 · Cited by 326
“Because IL-17 can induce IL-6 from tumor and stromal cells, STAT3 activation by IL-6 was proposed as one of mechanisms for protumorigenic role of IL-17 (22).”
BackgroundIL‐17 and IL‐22 in immunity: Driving protection and pathology
Eyerich, K., Dimartino, V., & Cavani, A. (2017) · European Journal of Immunology · doi:10.1002/eji.201646723 · Cited by 326
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311
Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3
Jiang, R., Tan, Z., Deng, L., Chen, Y., Xia, Y., Gao, Y., Wang, X., & Sun, B. (2011) · Hepatology · doi:10.1002/hep.24486 · Cited by 310
Li, S., Cong, X., Gao, H., Lan, X., Li, Z., Wang, W., Song, S., Wang, Y., Li, C., Zhang, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1003-0 · Cited by 299
IL-12 Family Cytokines in Cancer and Immunotherapy
Mirlekar, B., & Pylayeva-Gupta, Y. (2021) · Cancers · doi:10.3390/cancers13020167 · Cited by 295
Cytokines, Inflammation and Colon Cancer
Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 289
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Priebe, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0734 · Cited by 282
Yi, T., Chen, Y., Wang, L., Du, G., Huang, D., Zhao, D., Johnston, H., Young, J., Todorov, I., Umetsu, D. T., et al. (2009) · Blood · doi:10.1182/blood-2009-05-219402 · Cited by 280
Self-citationRoussel, L., Houle, F., Chan, C., Yao, Y., Bérubé, J., Olivenstein, R., Martin, J. G., Huot, J., Hamid, Q., Ferri, L., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903162 · Cited by 272
Th17 cells in inflammation and autoimmunity
Singh, R. P., Hasan, S., Sharma, S., Nagra, S., Yamaguchi, D. T., Wong, D. T. W., Hahn, B. H., & Hossain, A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.019 · Cited by 266
IL-17A Produced by γδ T Cells Promotes Tumor Growth in Hepatocellular Carcinoma
Ma, S., Cheng, Q., Cai, Y., Gong, H., Wu, Y., Yu, X., Shi, L., Wu, D., Dong, C., & Liu, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2534 · Cited by 264
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Habanjar, O., Bingula, R., Decombat, C., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044002 · Cited by 263
Th17 Cell Plasticity and Functions in Cancer Immunity
Guéry, L., & Hugues, S. (2015) · BioMed Research International · doi:10.1155/2015/314620 · Cited by 261
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites
Deng, J., Liu, Y., Lee, H., Herrmann, A., Zhang, W., Zhang, C., Shen, S., Priceman, S. J., Kujawski, M., Pal, S. K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.039 · Cited by 252
Self-citationCalcinotto, A., Brevi, A., Chesi, M., Ferrarese, R., Garcia Perez, L., Grioni, M., Kumar, S., Garbitt, V. M., Sharik, M. E., Henderson, K. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07305-8 · Cited by 223
Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth
Li, Y., Elmén, L., Segota, I., Xian, Y., Tinoco, R., Feng, Y., Fujita, Y., Segura Muñoz, R. R., Schmaltz, R., Bradley, L. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.035 · Cited by 189
“High serum levels of IL-6 and IL-17 were previously associated with poor clinical outcome (Rutkowski et al., 2015; Wang et al., 2009), whereas reduced IL-1 α levels were associated with attenuated tumor growth (Apte et al., 2006).”
Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers
Murlidhar, V., Reddy, R. M., Fouladdel, S., Zhao, L., Ishikawa, M. K., Grabauskiene, S., Zhang, Z., Lin, J., Chang, A. C., Carrott, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2072 · Cited by 181
“Enrichment of the IL-17 signaling pathway is also suggestive 448 of the invasiveness of the clusters, as it has been shown that IL-17 encourages metastasis and is 449 associated with poor survival (55,56).”
IL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type
Fabre, J., Giustiniani, J., Garbar, C., Antonicelli, F., Merrouche, Y., Bensussan, A., Bagot, M., & Al-Dacak, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091433 · Cited by 159
Lu, Y., Hong, B., Li, H., Zheng, Y., Zhang, M., Wang, S., Qian, J., & Yi, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317431111 · Cited by 146
IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells
Chen, X., Cai, G., Liu, C., Zhao, J., Gu, C., Wu, L., Hamilton, T. A., Zhang, C.-J., Ko, J., Zhu, L., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20171849 · Cited by 106
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
IL-17RC: a partner in IL-17 signaling and beyond
Ho, A. W., & Gaffen, S. L. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-009-0185-0 · Cited by 104
“Furthermore, in the murine B16 melanoma tumor model, IL-17A mediates a protumor function that involves IL-6 induction to activate Stat3 in both tumor cells as well as the tumor microenvironment [52].”
Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1277 · Cited by 80
Self-citationKrupar, R., Robold, K., Gaag, D., Spanier, G., Kreutz, M., Renner, K., Hellerbrand, C., Hofstaedter, F., & Bosserhoff, A. K. (2014) · Virchows Archiv · doi:10.1007/s00428-014-1630-6 · Cited by 75
Kim, K.-J., Kwon, S.-H., Yun, J.-H., Jeong, H.-S., Kim, H.-R., Lee, E. H., Ye, S.-K., & Cho, C.-H. (2017) · Oncogene · doi:10.1038/onc.2017.148 · Cited by 70
A positive feedback loop of IL-17B-IL-17RB activates ERK/β-catenin to promote lung cancer metastasis
Yang, Y.-F., Lee, Y.-C., Lo, S., Chung, Y.-N., Hsieh, Y.-C., Chiu, W.-C., & Yuan, S.-S. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.037 · Cited by 52
Delgado-Ramirez, Y., Baltazar-Perez, I., Martinez, Y., Callejas, B. E., Medina-Andrade, I., Olguín, J. E., Delgado-Buenrostro, N. L., Chirino, Y. I., Terrazas, L. I., & Leon-Cabrera, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147695 · Cited by 19
Metadata
- Authors
- Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2009-06-29
- Volume
- 206
- Issue
- 7
- Pages
- 1457-1464
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2151055438
- Cited by
- 842
- References
- 30
- FWCI
- 27.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.